FULGENT GENETICS, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- FULGENT GENETICS, INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $23.80M, a 979.59% increase year-over-year.
- FULGENT GENETICS, INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $40.08M, a 361.78% increase year-over-year.
- FULGENT GENETICS, INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- FULGENT GENETICS, INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00.
- FULGENT GENETICS, INC. payments for repurchase of common stock for fiscal 2025 was $10.88M, a 4737.33% increase from fiscal 2024.
- FULGENT GENETICS, INC. payments for repurchase of common stock for fiscal 2024 was $225.00K, a 99.10% decline from fiscal 2023.
- FULGENT GENETICS, INC. payments for repurchase of common stock for fiscal 2023 was $25.06M, a 66.29% decline from fiscal 2022.
- FULGENT GENETICS, INC. payments for repurchase of common stock for fiscal 2022 was $74.34M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $23.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $63.88M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $40.08M 10-Q · filed 2026-05-01 | $42.28M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $10.88M 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $10.88M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $10.88M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $8.68M 10-Q · filed 2026-05-01 | $8.68M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $225.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $23.09M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | |
| 2024-03-31 | $225.00K 10-Q · filed 2025-05-02 | |
| 2023-12-31 | $22.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $25.06M 10-K · filed 2026-02-27 |
| 2022-12-31 | $29.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $74.34M 10-K · filed 2025-02-28 |
| 2022-09-30 | $34.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | |
| 2021-03-31 | $513.00K 10-Q · filed 2021-05-07 | $529.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2020-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $62.00K 10-K · filed 2021-03-08 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | |
| 2020-03-31 | $46.00K 10-Q · filed 2021-05-07 | |
| 2019-12-31 | $21.00K 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |